Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 25, 2026
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
View original at globenewswire.comAscentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million)Sales of Olverembatinib increased 81%year-over-year to US$62.2 million (RMB435.3 million) Sales of Lisa…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The company is actively pursuing the inclusion of Lisaftoclax in China's NRDL
60% confidenceMultiple advancements are continuing across our de-risked late-stage pipeline
60% confidence2025 was a year of significant execution in advancing our mission to deliver innovative therapies to patients worldwide
60% confidenceLisaftoclax is the first Bcl-2 inhibitor to receive conditional approval and marketing authorization for the treatment of patients with CLL/SLL in China, and the second Bcl-2 inhibitor approved globally
60% confidenceOlverembatinib gained significant traction after receiving NRDL coverage expansion, which has markedly enhanced affordability and accessibility for patients in China
60% confidence